Fevipiprant

Unassigned

New Medicines

Nasal polyposis with chronic rhinosinusitis (CRSwNP) and concomitant asthma

Information

New molecular entity
Novartis
Novartis

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Feb 20Development of fevipiprant discontinued as PIII LUSTER studies (in patients with asthma) failed to met primary outcome [3].

Category

A CRTh2 antagonist; also termed DP2 antagonist, targets prostaglandin D2 receptors
Nasal polyps are lesions arising from the nasal mucosa, occurring at any site in the nasal cavity or paranasal sinuses but most frequently seen in the clefts of the middle meatus. Nasal polyps can be considered as part of the spectrum of chronic rhinosinusitis. The population prevalence is reported as around 4%, with no racial predilection. The male-to-female ratio is approximately 2:1 [1].
Nasal polyposis with chronic rhinosinusitis (CRSwNP) and concomitant asthma
Oral